ArticleInternational cancer conference journal2025
Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the efficacy and tolerability of low-dose oral cyclophosphamide, with or without bevacizumab, in treating recurrent ovarian and cervical cancer among patients heavily pretreated with platinum-based chemotherapy. It presents case reports of individuals who received low-dose cyclophosphamide (50 mg/day) and bevacizumab (15 mg/kg per cycle for three to four weeks) in a metronomic treatment approach. Focusing on three significant cases from a cohort of eleven treated with these regimens, the case report demonstrates partial responses, delayed disease progression, and minimal adverse effects. These findings highlight the regimen's potential to maintain quality of life and performance status. The study underscores the therapeutic benefits and mild toxicity profile of low-dose cyclophosphamide with or without bevacizumab, suggesting its potential as a viable treatment option for patients with extensive treatment history. This regimen is particularly promising in settings prioritizing quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.